Inter J Stomatol ›› 2017, Vol. 44 ›› Issue (1): 63-68.doi: 10.7518/gjkq.2017.01.014
• ·Treatment Studies • Previous Articles Next Articles
Zhang Xuefeng, Wang Jiongke, Zeng Xin, Chen Qianming.
CLC Number:
| [1] Martin LK, Werth VP, Villaneuva EV, et al. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus[J]. J Am Acad Dermatol, 2011, 64(5):903-908. [2] Scully C, Mignogna M. Oral mucosal disease: pem-phigus[J]. Br J Oral Maxillofac Surg, 2008, 46(4): 272-277. [3] Yeh SW, Sami N, Ahmed RA. Treatment of pem-phigus vulgaris: current and emerging options[J]. Am J Clin Dermatol, 2005, 6(5):327-342. [4] Scully C, Paes De Almeida O, Porter SR, et al. Pem-phigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions[J]. Br J Dermatol, 1999, 140(1):84-89. [5] Mignogna MD, Lo Muzio L, Mignogna RE, et al. Oral pemphigus: long term behaviour and clinical response to treatment with deflazacort in sixteen cases[J]. J Oral Pathol Med, 2000, 29(4):145-152. [6] Fardet L, Fève B. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events[J]. Drugs, 2014, 74(15):1731-1745. [7] Uchida K, Nakajima H, Miyazaki T, et al. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study[J]. J Nucl Med, 2009, 50(11): 1808-1814. [8] Panthakalam S, Bhatnagar D, Klimiuk P. The preva-lence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy [J]. Scott Med J, 2004, 49(4):139-141. [9] Uzu T, Harada T, Sakaguchi M, et al. Glucocor-ticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases[J]. Nephron Clin Pract, 2007, 105(2):c54-c57. [10] Reynolds RM, Labad J, Sears AV, et al. Glucocor-ticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh Type 2 Diabetes Study[J]. Eur J Endocrinol, 2012, 166(5):861-868. [11] Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them[J]. Cleve Clin J Med, 2011, 78(11): 748-756. [12] Committee for Guidelines for the Management of Pemphigus Disease, Amagai M, Tanikawa A, et al. Japanese guidelines for the management of pemphi-gus[J]. J Dermatol, 2014, 41(6):471-486. [13] Bevier WC, Zisser HC, Jovanovic L, et al. Use of continuous glucose monitoring to estimate insulin requirements in patients with type 1 diabetes mellitus during a short course of prednisone[J]. J Diabetes Sci Technol, 2008, 2(4):578-583. [14] Buehring B, Viswanathan R, Binkley N, et al. Gluco-corticoid-induced osteoporosis: an update on effects and management[J]. J Allergy Clin Immunol, 2013, 132(5):1019-1030. [15] Suzuki Y, Nawata H, Soen S, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update[J]. J Bone Miner Metab, 2014, 32(4):337-350. [16] Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the manage-ment of sys-temic glucocorticoid therapy in rheumatic diseases [J]. Ann Rheum Dis, 2007, 66(12):1560-1567. [17] Fardet L, Petersen I, Nazareth I. Monitoring of pa-tients on long-term glucocorticoid therapy: a popula-tion-based cohort study[J]. Medicine(Baltimore), 2015, 94(15):e647. [18] Chan KL, Mok CC. Glucocorticoid-induced avascu-lar bone necrosis: diagnosis and management[J]. Open Orthop J, 2012, 6:449-457. [19] Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis[J]. Semin Arthritis Rheum, 2002, 32(2):94-124. [20] Migita K, Sasaki Y, Ishizuka N, et al. Glucocorticoid therapy and the risk of infection in patients with newly diagnosed autoimmune disease[J]. Medicine (Baltimore), 2013, 92(5):285-293. [21] McDougall R, Sibley J, Haga M, et al. Outcome in patients with rheumatoid arthritis receiving predni-sone compared to matched controls[J]. J Rheumatol, 1994, 21(7):1207-1213. [22] Morand EF. Corticosteroids in the treatment of rheu-matologic diseases[J]. Curr Opin Rheumatol, 2000, 12(3):171-177. [23] Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids [J]. Rev Infect Dis, 1989, 11(6):954-963. [24] Fardet L, Cabane J, Kettaneh A, et al. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome[J]. Rheumatology: Oxford, 2007, 46(7):1102-1106. [25] Sato A, Funder JW, Okubo M, et al. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hyper-tension[J]. Am J Hypertens, 1995, 8(8):823-828. [26] Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose gluco-corticoid therapy associates with hypertension in patients with rheumatoid arthritis[J]. Rheumato-logy: Oxford, 2008, 47(1):72-75. [27] Carli L, Tani C, Querci F, et al. Analysis of the preva-lence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists’ practice for the monitoring of glucocorticoid eye toxicity[J]. Clin Rheumatol, 2013, 32(7):1071-1073. [28] Fel A, Aslangul E, Le Jeunne C. Eye and cortico-steroid’s use[J]. Presse Med, 2012, 41(4):414-421. [29] Zode GS, Sharma AB, Lin X, et al. Ocular-specific ER stress reduction rescues glaucoma in murine glucocorticoid-induced glaucoma[J]. J Clin Invest, 2014, 124(5):1956-1965. [30] Johnson LN, Soni CR, Johnson MA, et al. Short-term use of inhaled and intranasal corticosteroids is not associated with glaucoma progression on optical coherence tomography[J]. Eur J Ophthalmol, 2012, 22(5):695-700. [31] Olsen M, Christensen S, Riis A, et al. Preadmission use of systemic glucocorticoids and 30-day mortality following bleeding peptic ulcer: a population-based cohort study[J]. Am J Ther, 2010, 17(1):23-29. [32] van der Goes MC, Jacobs JW, Boers M, et al. Moni-toring adverse events of low-dose glucocorti-coid therapy: EULAR recommendations for clinical trials and daily practice[J]. Ann Rheum Dis, 2010, 69(11): 1913-1919. [33] Zaki SM, Mohamed EA. Effect of glucocorticoids on indomethacin-induced gastric ulcer in the adult male albino rat-histological, morphometric and elec-tron microscopy study[J]. Arch Med Sci, 2014, 10 (2):381-388. [34] Brenner PF. Differential diagnosis of abnormal ute-rine bleeding[J]. Am J Obstet Gynecol, 1996, 175(3 Pt 2):766-769. [35] Shwayder JM. Pathophysiology of abnormal uterine bleeding[J]. Obstet Gynecol Clin North Am, 2000, 27(2):219-234. [36] Warner P, Weir CJ, Hansen CH, et al. Low-dose dexamethasone as a treatment for women with heavy menstrual bleeding: protocol for response-adaptive randomised placebo-controlled dose-finding parallel group trial(DexFEM)[J]. BMJ Open, 2015, 5(1):e006837. [37] Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommen-dations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases[J]. Ann Rheum Dis, 2013, 72(12):1905-1913. [38] Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years[J]. Rheumatology(Oxford), 2011, 50(11):1982-1990. [39] Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective[J]. Arthritis Care Res(Hobo-ken), 2013, 65(2):294-298. [40] Fardet L, Cabane J, Lebbé C, et al. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study[J]. J Am Acad Dermatol, 2007, 57(4):604-609. |
| [1] | Wang Jiongke, Zhang Xuefeng, Chen Qianming, Zeng Xin.. Dosage and course of treatment—treating oral pemphigus vulgaris with systemic glucocorticoid therapy [J]. Inter J Stomatol, 2017, 44(1): 69-74. |